FDA Approves Large Studies of Ecstasy to Treat PTSD
Large-scale Phase 3 clinical trials of the illegal party drug Ecstasy as a treatment for post-traumatic stress disorder (PTSD) were approved Tuesday by the U.S. Food and Drug Administration.
Some small studies have yielded promising results. If the new trials are successful, Ecstasy (MDMA) could be approved as a prescription drug for PTSD, The New York Times reported.
An FDA spokeswoman declined to comment on the matter, citing rules that forbid providing information about drugs under development.
Click here to Read the full article: FDA Approves Large Studies of Ecstasy to Treat PTSD
Share this entry
- Diana Mercurio, BS, RPH, CDE, CDOE, CVDOE is Appointed to the American Health Council’s Industry Board November 13, 2018
- The American Health Council welcomes Ms. Amy Gordon onto the Industry Board November 9, 2018
- Dr. Amy Garza is appointed to the American Health Council Physical Therapy Board November 9, 2018
- The American Health Council welcomes Ms. Meladie Mitchell to the Nursing Board November 9, 2018
- The American Health Council welcomes Dr. Jeffrey Stenback onto the Physical Therapy Board November 8, 2018
- Dr. Deborah Riczo is appointed to the American Health Council’s Physical Therapy Board November 8, 2018